Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

NASDAQ: CRME TSX: COM

VANCOUVER and DEERFIELD, IL, June 04, 2007 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. ("Astellas") today announced results from their recently completed Phase 3 clinical study, called ACT 2. The trial evaluated the efficacy and safety of the intravenous formulation of vernakalant hydrochloride ("vernakalant (iv)") for the treatment of patients who developed atrial fibrillation or atrial flutter between 24 hours and 7 days following coronary artery bypass graft (CABG) or valve replacement surgery. In the atrial fibrillation population, 47% of patients dosed with vernakalant (iv) experienced conversion to normal heart rhythm within 90 minutes, as compared to 14% of placebo patients, a statistically significant difference (p=0.0001).

The ACT 2 study data suggests that vernakalant (iv) was well-tolerated in the studied patient population. In the 30-day interval following drug administration, serious adverse events occurred in 9% of all patients dosed with vernakalant (iv) and 11% of all placebo patients. Potentially drug-related serious adverse events occurred in 2% of patients who received vernakalant (iv) and 0% of placebo patients. There were no cases of drug-related "Torsades de Pointes", a specific and well-characterized ventricular arrhythmia.

The study achieved its primary endpoint in the combined atrial fibrillation and atrial flutter groups, showing that 45% of patients receiving vernakalant (iv) converted to normal heart rhythm within 90 minutes, as compared to 15% of placebo patients within the same time period (p=0.0002). Of the 10 patients in the atrial flutter population, no patients in the drug group and one patient in the placebo group converted to normal heart rhythm. A total of 190 patients were randomized in the study, of which 161 received treatment.

In the patients treated with vernakalant (iv
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:7/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ) ... ended June 28, 2014. Third Quarter Financial ... to $632.6 million, reflecting operational growth of 0.5% and ... same period in the prior year. , Revenues ... Breast Health revenues grew 3.5%. , GYN Surgical ...
(Date:7/30/2014)... July 30, 2014 In conjunction with DURECT ... financial results press release, you are invited to listen ... over the internet on Thursday, August 7, 2014 at ... A live audio webcast of the presentation will ... and clicking "Investor Relations."  If you are unable ...
(Date:7/30/2014)... , July 30, 2014 PuraMed ... and marketer of over-the-counter (OTC) medicinal and healthcare ... ® M name along with the name,s ... replaced with the trademarked name MigraPure ® ... palette of PuraMed,s homeopathic, natural migraine pain reliever ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3
... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Triple ... http://www.reportlinker.com/p0284621/Triple-Analysis-Leukemia-Lymphoma-and-Peptides.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology This ... strategies in both Leukemia and Lymphoma and ...
... Calif., May 23, 2011 Applied Medical today announced ... business as Covidien) on May 17, 2011 in the ... for infringing a recently issued Applied Medical trocar seal ... products, Civil Action No. CV 11-4203 VBF (AJWx). The ...
Cached Medicine Technology:Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 2Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 3Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 4Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides 5Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent 2
(Date:7/31/2014)... 2014 “Bivalent, Heteronomy and Natural Killer ... hottest metal bands ~ homeostatic CS science is the ... July Roundup, new on the Bryan William Brickner ... and the cannabinoid system (CS). The line-up links to ... wellness: three directly on homeostasis, two each on the ...
(Date:7/31/2014)... latest blog post, Best Drug Rehabilitation , which offers ... a stay in rehab can make a big difference in ... nine secrets that addicts don’t want others to know. ... addict from a mile away, and totally understand what’s going ... Per Wickstrom . “However, take it from me: spotting addicts ...
(Date:7/31/2014)... 31, 2014 Continuing Education Company ... inaugural Clinical Issues in Primary Care Continuing ... 2014 at the Wailea Beach Marriott Resort and Spa ... has been developed for today's Primary Care practitioners. In ... topics," says Barbara Lyons, VP Education. , The agenda ...
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 ... the skiers wearing orange vests emblazoned with “Blind Skier.” ... Colorado slopes through Foresight Ski Guides , a ... with visually impaired and blind participants (VIPs) for snow ... interested in guiding can learn more and pick up ...
(Date:7/30/2014)... July 31, 2014 Responding to ... environment more responsive to an increasingly diverse patient ... experience and scholarly expertise to the publication of ... care professions: "Diversity and Cultural Competence in Health ... L. Dreachslin, PhD, a professor in the Management ...
Breaking Medicine News(10 mins):Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 2Health News:Latest Best Drug Rehabilitation Blog Posts Focuses on Nine Secrets Addicts Don’t Want Others to Know 3Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Colorado Non-Profit Foresight Ski Guides Seeking Applications for Blind and Visually Impaired Skiers and Guides for Vail Ski Season 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3
... Health & Science University researchers have determined exactly how much ... results of this research are being presented from 5 p.m. ... for Therapeutic Radiology and Oncology in Boston. , "Many ... that it doesn,t move in relation to the bony pelvis, ...
... is playing an ever smaller role in the treatment ... and safe radiation therapy techniques. Progress in radiation technology ... This is according to Professor Freek Beekman, who will ... on Wednesday, 24 September. , In his inaugural ...
... bacteria that drive the ailment, study shows , , WEDNESDAY, ... sweet relief to chronic sinusitis sufferers, new Canadian research ... attack the bacteria that cause the discomforting disorder. , ... natural anti-microbial dressing for infected wounds for hundreds of ...
... 24 TransEnterix, an,early-stage, privately-held medical device company ... the Board of Directors has,named Todd M. Pope ... Pope has spent nearly 20 years in the ... neurovascular, and,laparoscopic surgery., Mr. Pope, 43, was ...
... Indianapolis speech, INDIANAPOLIS, Sept. 24 Today Eli ... is set to become the first,pharmaceutical research company to ... At a speech before the Economic Club of Indiana ... outlined the,company,s plans to launch an online registry of ...
... Longstanding Barriers to ... Hearing Better, ... a unique option for people dealing with mild to moderate,hearing loss. ... hearing loss, while concerns about cost,commitments, and inconvenience contribute to only ...
Cached Medicine News:Health News:OHSU Cancer Institute researchers study breathing during radiation 2Health News:Open cancer surgery set to become a thing of the past 2Health News:A Honey of a Sinusitis Treatment 2Health News:A Honey of a Sinusitis Treatment 3Health News:TransEnterix Inc. Names Experienced Medical Device Executive Todd M. Pope as President, CEO 2Health News:Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments 2Health News:Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments 3Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 2Health News:Songbird Hearing Provides Revolutionary Alternative for Those Dealing With Hearing Loss 3
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
This blanket gently surrounds the child with temperature-controlled air. Use one or both of the enclosed clear plastic drapes to keep warmed air near the skin....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
The multi-access blanket offers access to any part of the patient's body while providing full patient coverage....
Medicine Products: